We remain constructive on the company given its diversified portfolio, healthy volume growth (9-10% over FY20-22E) and quality of customers. Robustness of its business enables GSL to maintain stable margins (EBITDAM of ~12.5 expected over FY20-22E). Given the secular growth opportunity and its capability to generate 20%+ returns on reinvested profits, GSL's current PER of 19.8/17.3x FY21/22E is rather low. We value GSL at 22x Sep-21 EPS to arrive at a TP of Rs 1,834. Maintain BUY. Galaxy Surfactants (GSL) 2QFY20 performance was commendable with >10% YoY volume growth amidst slowdown in the global Home and Personal care (HPC) market. GSL maintained a cautious domestic demand outlook for 2HFY20 but a gradual shift in consumption pattern towards specialty care products will help maintain profitability in the long run. Other geographies, however, will continue to support volume growth in 2H.